Postpartum Acquired Hemophilia A.

Area of Science:

• Hematology
• Obstetrics

Background:

• Acquired hemophilia A (AHA) is an autoimmune disorder targeting factor VIII, leading to bleeding complications.
• Postpartum presentation of AHA is rare but documented, with unclear underlying causes.
• Coexistence of AHA with other hematological disorders, like sickle cell trait (SCT), is exceptionally uncommon.

Observation:

• A pregnant patient with a history of SCT presented with intractable postpartum hemorrhage after a Cesarean section.
• Initial laboratory findings revealed isolated prolonged activated partial thromboplastin time (aPTT).
• Further tests confirmed reduced factor VIII activity and the presence of factor VIII inhibitors, indicative of AHA.

Findings:

• The patient was diagnosed with postpartum acquired hemophilia A (PAH).
• Treatment involved activated Factor VII and prednisone to achieve hemostasis and target inhibitors.
• PAH typically manifests 1-4 months postpartum with excessive bleeding, prolonged aPTT, abnormal mixing studies, and high inhibitor levels.

Implications:

• This case highlights the critical importance of considering AHA in postpartum hemorrhage, even in patients with coexisting hematological conditions.
• While the association between AHA and SCT is not fully understood, severe bleeding events underscore the need for vigilant management.
• Further research is needed to elucidate the interplay between AHA and other hematological disorders and optimize treatment strategies.